Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-19
2010-10-05
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000
Reexamination Certificate
active
07807642
ABSTRACT:
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
REFERENCES:
patent: 4810781 (1989-03-01), Hollinshead
patent: 6312937 (2001-11-01), Ni et al.
patent: 6746852 (2004-06-01), Cismowski et al.
patent: 2004/0208862 (2004-10-01), Brady-Kalnay et al.
patent: 19936563 (2001-08-01), None
patent: WO 0157275 (2001-09-01), None
patent: WO 0157276 (2001-09-01), None
patent: WO 02/50103 (2002-06-01), None
patent: WO 02078516 (2002-10-01), None
patent: WO/02/094981 AS (2002-11-01), None
Yamane et al .(Proc. Natl. Acad. Sci. USA 1991; 88: 286-290).
Cheever et al. “T-Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR-ABLa”, Annals N.Y. Acad. Sci. 1993 690:101-112. .
Kobayashi et al., “Identification of an Antigenic Epitope for Helper T Lymphocytes From Carcinoembryonic Angigen”, 2002, Clinical Cancer Research; 8:3219-3225.
Gnjatic et al., “Survey of Naturally Occurring CD4+ T-Cell Responses Against NY-ESO-1 Cancer Patiencs: Correlation With Antibody Responses”, 2003, Proc. Natl. Acad. Sci. U.S.A. 100(15):8862-7.
Qin et al., “CD4+ T Cell-Mediated Tumor Rejection Involves Inhibition of Angiogenesis That is Dependent on IFNY Receptor Expression by Nonhematopoietic Cells”, Immunity vol. 12 677-686 Jun. 2000.
Kennedy et al., “CD4+ T Lymphocytes Play a Critical Role in Antibody Production and Tumor Immunity Against Simian Virus 40 Large Tumor Antigen”. Cancer Research 63, 1040-1045, Mar. 1, 2003.
Mach et al., “Regulation of MHC Class II Genes: Lessons From A Disease” Annu. Rev. Immunol, 1996 14:301-31.
Chaux et al., “Identification of Mage-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes”, J.Exp.Med. vol. 189, No. 5, Mar. 1, 1999 189:767-778.
Vigneron et al., “An Antigenic Peptide Produced by Peptide Splicing in the Proteasome”, Science vol. 304, Apr. 23; 304 (5670):587-90.
Linehan et al., “Genetic Basis of Cancer of the Kidney: Disease-Specific Approaches to Therapy”, American Association for Cancer Research, vol. 10, 6282s-6289s, Sep. 15, 2004.
McCarty et al., “Targeting P53 for Adoptive T-Cell Immunotherapy”, Cancer Research 58 1998 15:58 2601-5.
Disis et al., “Immunity to the Her-2/Neu Oncogenic Protein”, Ciba Found. Symp. 1994 187:198-211.
Marks et al., “A Lysosomal Targeting Signal in the Cytoplasmic Tail of the B Chain Directs HLA-DM to MHC Class II Compartments”, 1995, J. Cell Biol. 131, 351-369.
Rodriguez et al., “DNA Immunization With Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection are Rectified by Ubiquitination”, 2001, Journal of Virology Jun. 1998, 5174-5181.
Parker et al; Scheme for Ranking Potential . . . Peptide Side-Chains, Journal of Immunology; XP-00088437; 1994; pp. 163-175.
Park et al., Sequence of MET protooncogene cDNA . . . receptors; Proc. Natl. Acad. Sci. USA; XP-000941506; 1978; pp. 6379-6383.
Held et al.; Adipocyte differentiation-related . . . membrane; Biochem J.; XP-002060680; 1996, pp. 1025-1030.
Database online; Human mRNA for KIAA0367 gene . . . ; XP-002353163; pp. 1-3, May 9, 2002.
Weinschenk et a l.; Integrated Functional . . . Antitumor Vaccines; Cancer Research, vol. 62; Oct. 15, 2002; pp. 5818-5827.
Schirle et al.; Identification of tumor-associated . . . approach; Eur. J. Immunol., vol. 30, XP-002246625; 2000; pp. 2216-2225.
Schmidt et al.; Induction of Adipophilin-Specific . . . Cell Lysis; Cancer Research, vol. 64, Feb. 1, 2004; pp. 1164-1170.
Kobayashi et al.; “Defining promiscous . . . Antigen,” Cancer Research, Sep. 15, 2000, vol. 60, pp. 5228-5236.
Database Geneseq [online] Derwent; Jan. 23, 2003; XP002365849.
Database Geneseq [online] Derwent; Feb. 12, 2004; X002405482.
Database Geneseq [online] Derwent; Nov. 5, 2001; XP002365851.
Database Geneseq [online] Derwent; Nov. 6, 2001; XP002365850.
Database Geneseq [online] Derwent; Aug. 12, 2004; XP002425882.
Baker Donelson Bearman Caldwell & Berkowitz PC
Fetterolf Brandon J
Immatics Biotechnologies GmbH
LandOfFree
Tumor-associated peptides binding promiscuosly to human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor-associated peptides binding promiscuosly to human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-associated peptides binding promiscuosly to human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242117